Skip to main content

Table 2 Laboratory data in patients and control group

From: GDF-15 and hepcidin as a therapeutic target for anemia in chronic kidney disease

Median (IQR)

Group I (Cases

N = 60

Group II (Control)

N = 28

p value

Hb (g/dL)

9.8

(9.0—10.5)

12.1

(11.9 – 12.3)

 < 0.0001*

MCV (fL)

85.0

(79.3 – 88.0)

88.0

(85.0 – 92.0)

0.003*

MCH

27.0

(26.0 – 29.0)

28.5

(28.0 – 30.8)

 < 0.001*

MCHC

32.0

(30.3 – 33.0)

33.0

(33.0 – 35.0)

 < 0.0001*

Urea (mg/dl)

96.5

(39.8 – 124.3)

25.5

(25.0 – 28.0)

 < 0.0001*

Creat (mg/dl)

2.2

(0.9 – 4.3)

0.6

(0.5 – 0.7)

 < 0.0001*

eGFR (ml/min)

28.6

(22.3 – 67.2)

130.0

(120.8 – 152.3)

 < 0.0001*

A/C ratio

322.0

(153.0 – 1073.0)

–––

–––-

ALT (U/L)

22.0

(15.0 – 30.0)

22.0

(18.5 – 27.0)

0.689

AST (U/L)

25.0

(21.0 – 33.0)

23.5

(18.8 – 27.8)

0.119

Iron (µg/dL)

52.0

(36.0 – 88.3)

100.0

(85.8 – 106.8)

 < 0.0001*

Ferritin (μg/l)

755.0

(181.5 – 1330.5)

95.0

(88.0 – 102.0)

 < 0.0001*

TIBC (µg/dL)

254.0

(187.8 – 287.5)

161.5

(153.5 – 189.5)

 < 0.0001*

Transferrin

25.0

(16.3 – 42.0)

25.0

(19.0 – 34.3)

0.74

CRP (mg/l)

12.0

(3 – 24.0)

3 (2—5)

 < 0.0001*

Hepcidin (ng/mL)

338.5

(276.0 – 505.5)

303.0

(215.0 – 387.0)

0.047*

GDF (ng/L)

1277.2

(1072.3 – 1376.6)

401.6

(298.6 – 594.5)

 < 0.0001*

  1. * significant level at P value <0.05